Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

BerGenBio doses first patient in Phase II bemcentinib trial

Blood smear from a person with myelodysplastic syndrome. Credit: The Armed Forces Institute of Pathology (AFIP).



  • BerGenBio

Go Top